Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06701656 · ClinicalTrials.gov registry record · Phase 2

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

A Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, sponsored by PPD Development.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT06701656 is a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS that is actively recruiting participants, run by PPD Development. The registered enrollment target is 200 participants, below the 361-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06701656, a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, is actively recruiting participants, sponsored by PPD Development.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort C: Participants will be randomized to receive either a placebo or bevacizumab. This record describes the default procedures and analyses for Cohort C. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.

Conditions Studied

Acute Respiratory Distress Syndrome ARDS Acute Respiratory Distress Syndrome (ARDS) ARDS (Acute Respiratory Distress Syndrome)

Interventions

  • DRUG Cohort C: bevacizumab
  • DRUG Cohort C: placebo

Study Locations (20)

California

  • Community Regional Medical Center - Fresno
  • Long Beach Memorial Medical Center - Long Beach
  • University of California Irvine Medical Center - Orange
  • University of California Davis Medical Center - Pulmonary Medicine - Sacramento

Florida

  • Nova Clinical Research - Bradenton
  • North Florida / South Georgia Veterans Health System - Gainesville
  • Sarasota Memorial Hospital - Sarasota

Massachusetts

  • Tufts Medical Center - Boston
  • Lahey Hospital and Medical Center - Burlington

Michigan

  • University of Michigan Hospital - Ann Arbor
  • Henry Ford Health Hospital - Detroit

Alabama

  • University of Alabama Hospital - Birmingham

Colorado

  • Denver Health Hospital and Authority - Denver

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Idaho

  • St. Luke's Boise Medical Center - Boise

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-10-28
Est. Completion 2028-09
Phase Phase 2

Sponsor

PPD Development

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06701656

The ClinicalTrials.gov registry entry for NCT06701656 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (45% lower). The listed sponsor is PPD Development, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Cohort C: bevacizumab is the first listed.

NCT06701656 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06701656 about?

NCT06701656 is a clinical study titled "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab". This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort C: Participants wil...

What is the current status of trial NCT06701656?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-10-28. Estimated completion is 2028-09.

What conditions does trial NCT06701656 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, ARDS, Acute Respiratory Distress Syndrome (ARDS), ARDS (Acute Respiratory Distress Syndrome).

What interventions are being tested in trial NCT06701656?

The interventions under investigation include: Cohort C: bevacizumab (DRUG), Cohort C: placebo (DRUG).

Who is sponsoring clinical trial NCT06701656?

This trial is sponsored by PPD Development, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06701656 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Respiratory Distress Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Respiratory Distress Syndrome

All registered trials for this condition

ARDS

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.